| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000017003 |
| Receipt No. | R000019691 |
| Scientific Title | Prospective cohort study to define the clinical and pathological features of lung cancers harboring HER2 gene aberrations. |
| Date of disclosure of the study information | 2015/04/01 |
| Last modified on | 2022/05/16 (Ver. 8) |
| Basic information | ||
| Public title | Prospective cohort study to define the clinical and pathological features of lung cancers harboring HER2 gene aberrations. | |
| Acronym | HER2-CS STUDY | |
| Scientific Title | Prospective cohort study to define the clinical and pathological features of lung cancers harboring HER2 gene aberrations. | |
| Scientific Title:Acronym | HER2-CS STUDY | |
| Region |
|
|
| Condition | ||
| Condition | Non-small-cell lung cancer | |
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Define that HER2 positivity of non-small cell lung cancer |
| Basic objectives2 | Others |
| Basic objectives -Others | Exploring the charatristics of HER2 postive non-small cell lung cancer |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Develpment of the criteria of HER2 postivity in NSCLC |
| Key secondary outcomes | |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Non-small cell lung cancer with pathological confirmation
2. No radical treatment indication 3. Performance status 0-2 4. Patient with document agreement for this study |
|||
| Key exclusion criteria | There are no special instruction regarding this section. | |||
| Target sample size | 1000 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Okayama University Hospital | ||||||
| Division name | Allergy and respiratory medicine | ||||||
| Zip code | 700-8558 | ||||||
| Address | 2-5-1 Shikata-cho, Kita-Ku,Okayama | ||||||
| TEL | 086-235-7227 | ||||||
| kkiura@md.okayama-u.ac.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Okayama University Hospital | ||||||
| Division name | Allergy and respiratory medicine | ||||||
| Zip code | 700-8558 | ||||||
| Address | 2-5-1 Shikata-cho, Kita-Ku,Okayama | ||||||
| TEL | 086-235-7227 | ||||||
| Homepage URL | |||||||
| khotta@md.okayama-u.ac.jp | |||||||
| Sponsor | |
| Institute | Okayama University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Health Labour Sciences Research Grant |
| Organization | |
| Division | |
| Category of Funding Organization | Japanese Governmental office |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Okayama University Hospital |
| Address | 2-5-2 Shikata-cho, Kita-Ku |
| Tel | 086-235-6503 |
| ecm6938@adm.okayama-u.ac.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | doi: 10.1016/j.chest.2019.01.011. |
| Publication of results | Published |
| Result | |||||||
| URL related to results and publications | https://www.sciencedirect.com/science/article/pii/S0012369219300315?via%3Dihub | ||||||
| Number of participants that the trial has enrolled | 1126 | ||||||
| Results | Of the 1,126 tumors screened, 34 (3.0%) were IHC3+, and 34 (3.0%) were IHC2+/FISH+. Among the 724 epidermal growth factor receptor wild-type tumors, 21 (2.9%) were HER2-mutant tumors, including A775-G776insYVMA (n = 15). Interestingly, the IHC3+ tumors and mutant tumors were entirely exclusive. Female patients had HER2-mutant tumors more frequently, whereas both IHC3+ and IHC2+/FISH+ tumors were detected more often in male subjects and smokers. | ||||||
| Results date posted |
|
||||||
| Results Delayed | |||||||
| Results Delay Reason | |||||||
| Date of the first journal publication of results |
|
||||||
| Baseline Characteristics | Patients with pathologically confirmed stage IIIB/IV or recurrent NSCLC, Eastern Cooperative Oncology Group performance status 0 to 2, were prospectively registered. | ||||||
| Participant flow | HER2 immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assays were performed to screen patients. | ||||||
| Adverse events | NA | ||||||
| Outcome measures | The aim of this study was to clarify the frequency, characteristics, and outcome of HER2-positive NSCLC. HER2 was defined as positive if the tumor harbored IHC3+, IHC2+/FISH+, or exon 20 insertion mutations. | ||||||
| Plan to share IPD | |||||||
| IPD sharing Plan description | |||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | Completed |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000019691 |